Prospective Registry Of Patients With Pancreas Adenocarcinoma Resectable And Borderline

Study Overview

Prospective Registry of Patients With Pancreas Adenocarcinoma Resectable and Borderline

Unlike other types of gastrointestinal tumors, there is controversial evidence of the efficacy of neoadjuvant therapy in patients with borderline and resectable adenocarcinoma (ADK) of the pancreas, the objective of this study is to perform a "snapshot" of the usual practice in our setting in terms of neoadjuvant therapy in ADK, both in terms of the different regimens used as well as the results in terms of morbidity, mortality and survival. Likewise, in a second phase, a prospective registry of patients included in the neoadjuvant regimen for both resectable and borderline ADK diagnosed in Catalonia will be launched, which will provide us with valuable information to try to answer open questions in the context of borderline and resectable ADK treatment.

N/A

Chemotherapy Effect
Pancreas Cancer

PROCEDURE: Neoadyuvant therapy

PaNLoCat_v4

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates	Results Reporting Dates	Study Record Updates
First Submitted 2022-08-03	Results First Submitted N/A	Last Update Submitted that met QC Criteria 2024-06-05
First Submitted that Met QC Criteria 2022-08-23	Results First Submitted that Met QC Criteria N/A	Last Update Posted (ACTUAL) 2024-06-07
First Posted (ACTUAL) 2022-08-24	Results First Posted N/A	Last Verified 2024-06

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
N/A

Allocation:
N/A

Interventional Model:
N/A

Masking:
N/A

Arms and Interventions

Participant Group/Arm	Intervention/Treatment
: Neoadyuvant therapy Patients with borderline or resectable ADK subjected to neoadyuvant therapy	PROCEDURE: Neoadyuvant therapy Patients of group neoadyuvant therapy will receive any chemotherapy treatment before surgery
: Upfront surgery Patients with borderline or resectable ADK who undergo upfront surgery

Participant Group/Arm

Intervention/Treatment

: Neoadyuvant therapy

Patients with borderline or resectable ADK subjected to neoadyuvant therapy

PROCEDURE: Neoadyuvant therapy

Patients of group neoadyuvant therapy will receive any chemotherapy treatment before surgery

: Upfront surgery

Patients with borderline or resectable ADK who undergo upfront surgery

Primary Outcome Measures	Measure Description	Time Frame
Disease free survival		Three years follow-up

Secondary Outcome Measures	Measure Description	Time Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

resectable or borderline pancreas ADK
with or without radiotherapy
any type of approach
any type of surgery

locally advanced ADK
No consent

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available

Learn

Resources

PatientS

Caregivers

Clinical Trial Record